The triad: Erectile dysfunction - Endothelial dysfunction - Cardiovascular disease

Current Pharmaceutical Design

Volumn 14, Issue 35, 2008, Pages 3700-3714

  Vlachopoulos, Charalambos ^a   Ioakeimidis, Nikolaos ^a   Terentes Printzios, Dimitrios ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Coronary artery disease; Endothelial dysfunction; Erectile dysfunction; Nitric oxide; Phosphodiesterase type 5 inhibitors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; N(G),N(G) DIMETHYLARGININE; NATRIURETIC PEPTIDE TYPE C; NEBIVOLOL; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN E2; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SILDENAFIL; TADALAFIL; TELMISARTAN; VARDENAFIL;

ANGINA PECTORIS; ARTERY BLOOD FLOW; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; EXERCISE; FLOW MEDIATED DILATATION; HUMAN; HYPERTENSION; INFLAMMATION; LIFESTYLE MODIFICATION; MEMBRANE MICROPARTICLE; MONOTHERAPY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PLEIOTROPY; PRIORITY JOURNAL; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEXUAL FUNCTION; SMOOTH MUSCLE RELAXATION; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; ADULT; AGED; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PENIS; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ADULT; AGED; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PENIS;

EID: 61449111233     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786898716     Document Type: Review

References (157)

1. National Institutes of Health Consensus Statement. Impotence 1992; 10: 1.
2. Kirby M, Jackson G, Simonsen U. Endothelial dysfunction links erectile dysfunction to heart disease. Int J Clin Pract 2005; 59: 225-229.
3. Montorsi P, Montorsi F, Schulman C. Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder? Eur Urol 2003; 44: 352-354.
4. Billups K, Bank A, Padma-Nathan H, Katz S, Williams R. Erectile dysfunction is a marker for cardiovascular disease: Results of the Minority Health Institute Expert Advisory Panel. J Sex Med 2005; 2: 40-52.
5. Solomon H, Man JW, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic artery disease. Am J Cardiol 2002; 91: 230-1.
6. Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360-5.
7. Kloner RA, Mullin SH, Shook T, Matthews R, Mayeda G, Burstein S, et al. Erectile dysfunction in the cardiac patient: How common and should we treat? J Urol 2003; 170: S46-50.
8. Bener A, Al-Hamaq AO, Kamran S, Al-Ansari A. Prevalence of erectile dysfunction in male stroke patients, and associated comorbidities and risk factors. Int Urol Nephrol 2008; 40: 701-8.
9. Araujo AB, Zilber SM, O'Donnell AB, McKinlay JB. Erectile dysfunction and stroke risk in aging men: Prospective results from the Massachusetts Male Aging Study. J Urol 2005; 173: 291. [abstract]
10. Sasayama S, Ishii N, Ishikura F, Kamijima G, Ogawa S, Kanmatsuse K, et al. Men's Health Study: Epidemiology of erectile dysfunction and cardiovascular disease. Circ J 2003; 67: 656-9.
11. Falkensammer J, Hakaim AG, Falkensammer CE, Broderick GA, Crook JE, Heckman MG, et al. Prevalence of erectile dysfunction in vascular surgery patients. Vasc Med 2007; 12: 17-22.
12. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2996-3002.
13. Gazzaruso C, Solerte SB, Pujia A, Coppola A, Vezzoli M, Salvucci F, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: A potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 2008; 51: 2040-4.
14. Blumentals WA, Gomez-Caminero A, Joo S, Vannappagari V. Is erectile dysfunction predictive of peripheral vascular disease? Aging Male. 2003; 6: 217-21.
15. Chew KK, Bremner A, Jamrozik K, Earle C, Stuckey B. Male erectile dysfunction and cardiovascular disease: Is there an intimate nexus? J Sex Med 2008; 5: 928-34.
16. Sáenz de Tejada I, Angulo J, Cellek S, González-Cadavid N, Heaton J, Pickard R, et al. Physiology of erectile function. J Sex Med 2004; 1: 254-65.
17. Prieto D. Physiological regulation of penile arteries and veins. Int J Impot Res 2008; 20: 17-29.
18. Maas R, Schwedhelm E, Albsmeier J, Boger RH. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 2002; 7: 213-25.
19. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and - independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179-84.
20. Chiurlia E, D'Amico R, Ratti C, Granata A, Romagnoli R, Modena M. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol 2005; 46: 1503-1506.
21. Yavuzgil O, Altay B, Zoghi M, Gürgün C, Kayikçioǧlu M, Kültürsay H. Endothelial function in patients with vasculogenic erectile dysfunction. Int J Cardiol 2005; 103: 19-26.
22. Kaya C, Uslu Z, Karaman I. Is endothelial function impaired in erectile dysfunction patients? Int J Impot Res 2006; 18: 55-60.
23. Mazo E, Gamidov S, Anranovich S, Iremashvili V. Testing endothelial function of brachial and cavernous arteries in patients with erectile dysfunction. J Sex Med 2006; 3: 323-30.
24. Uslu N, Eren M, Gorgulu S, Alper AT, Orhan AL, Yildirim A, et al. Left ventricular diastolic function and endothelial function in patients with erectile dysfunction. Am J Cardiol 2006; 97: 1785-8.
25. Esposito K, Ciotola M, Giugliano F, Sardelli L, Giugliano F, Maiorino MI, et al. Phenotypic assessment of endothelial microparticles in diabetic and nondiabetic men with erectile dysfunction. J Sex Med 2008; 5: 1436-42.
26. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, Rokkas K, Tsekoura D, Vasiliadou C, et al. Arterial function and intima-media thickness in hypertensive patients with erectile dysfunction. J Hypertens 2008; 26: 1829-36.
27. Friedewald VE, Giles TD, Pool JL, Yancy CW, Roberts WC. The Editor's Roundtable: Endothelial Dysfunction in Cardiovascular Disease. Am J Cardiol 2008; 102: 418-423.
28. Brocq ML, Leslie SJ, Milliken P, Megson IL. Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. Antioxid Redox Signal 2008; 10: 1631-74.
29. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: Endothelial dysfunction is the common denominator. Heart 2003; 89: 251-3.
30. Pritzker MR: The pAnile stress test: a window to the hearts of man. Circulation 1999; 100: I-171. [abstract]
31. Kawanishi Y, Lee KS, Kimura K, Koizumi T, Nakatsuji H, Kojima K, et al. Screening of ischemic heart disease with cavernous artery blood flow in erectile dysfunctional patients. Int J Impot Res 2001; 13: 100-103.
32. Kim SW, Paick JS, Park DW, Chae I, Oh B: Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. Urology 2001; 58: 441-445.
33. Shamloul R, Ghanem HM, Salem A, Elnashaar A, Elnaggar W, Darwish H, et al. Correlation between penile duplex findings and stress electrocardiography in men with erectile dysfunction. Int J Impot Res 2004; 16: 235-237.22.
34. Vlachopoulos C, Rokkas K, Ioakeimidis N, Aggeli C, Michaelides A, Roussakis G, et al. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: A prospective angiographic study. Eur Urol 2005; 48: 996-1002.
35. Jackson G, Padley S. Erectile dysfunction and silent coronary artery disease: Abnormal computed tomography coronary angiogram in the presence of normal exercise ECGs. Int J Clin Pract 2008; 62: 973-6.
36. Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A, et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: The COBRA trial. Eur Heart J 2006; 27: 2632-2639.
37. Vlachopoulos C, Ioakeimidis N, Stefanadis C. Erectile dysfunction and coronary artery disease: A relationship for disclosure. Hellenic J Cardiol 2008; 49: 1-6.
38. Montorsi P, Ravagnani PM, Galli S, Salonia A, Briganti A, Werba JP, et al. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol 2006; 50: 721-31.
39. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997; 157: 1920-5.
40. El Melegy NT, Ali ME, Awad EM. Plasma levels of endothelin- 1, angiotensin II, nitric oxide and prostaglandin E in the venous and cavernosal blood of patients with erectile dysfunction. BJU Int 2005; 96: 1079-86.
41. Kun A, Kiraly I, Pataricza J, Marton Z, Krassoi I, Varro A, et al. C-type natriuretic peptide hyperpolarizes and relaxes human penile resistance arteries. J Sex Med 2008; 5: 1114-25.
42. Burnett AL. Nitric oxide in the penis: Physiology and pathology. J Urol 1997; 157: 320-324.
43. Bocchio M, Desideri G, Scarpelli P, Necozione S, Properzi G, Spartera C, et al. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol 2004; 171: 1601-1604.
44. Musicki B, Burnett AL. eNOS function and dysfunction in the penis. Exp Biol Med (Maywood) 2006; 231: 154-65.
45. Watts GF, Chew KK, Stuckey B. The erectile-endothelial dysfunction nexus: New opportunities for cardiovascular risk prevention. Nat Clin Pract Cardiov Med 2007; 4: 263-273.
46. Tostes RC, Carneiro FS, Lee AJ, Giachini FR, Leite R, Osawa Y, et al. Cigarette smoking and erectile dysfunction: Focus on NO bioavailability and ROS generation. J Sex Med 2008; 5: 1284-95.
47. Burnett AL. Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 2004; 16: S15-S19.
48. Komori K, Tsujimura A, Takao T, Matsuoka Y, Miyagawa Y, Takada S, et al. Nitric oxide synthesis leads to vascular endothelial growth factor synthesis via the NO/cyclic guanosine 3′,5′monophosphate (cGMP) pathway in human corpus cavernosal smooth muscle cells. J Sex Med 2008; 5: 1623-35.
49. Jeremy JY, Angelini GD, Khan M, Mikhailidis DP, Morgan RJ, Thompson CS, et al. Platelets, oxidant stress and erectile dysfunction: An hypothesis. Cardiovasc Res 2000; 46: 50-4.
50. Jones RWA, Rees RW, Minhas S, Ralph D, Persad RA, Jeremy JY. Oxygen free radicals and the penis. Expert Opin Pharmacother 2002; 3: 889-97.
51. Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, Rokkas K, Aznaouridis K, Baou K, et al. NT-proCNP is associated with the presence, severity and duration of vasculogenic erectile dysfunction. [Eur Urol, in press]
52. Ioakeimidis N. The impact of C-type natriuretic peptide and endothelin- 1 levels on sexual performance in men with erectile dysfunction: A novel approach to erectile dysfunction. J Sex Med 2008. [abstract]
53. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
54. Foresta C, Caretta N, Lana A, Cabrelle A, Palu G, Ferlin A.. Circulating endothelial progenitor cells in subjects with erectile dysfunction. Int J Impot Res 2005; 17: 288-290.
55. Baumhäkel M, Werner N, Bohm M, Nickenig G. Circulating endothelial progenitor cells correlate with erectile function in patients with coronary heart disease. Eur Heart J 2006; 27: 2184-8.
56. Virag R, Floresco J, Richard G. Impairment of shear-stress mediated vasodilation of cavernous arteries in erectile dysfunction. Int J Impot Res 2004; 16: 39-42.
57. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 1314-1319.
58. Paniagua OA, Bryant MB, Panza JA. Role of endothelial nitric oxide in shear stress-induced vasodilation of human microvasculature: Diminished activity in hypertensive and hypercholesterolemic patients. Circulation 2001; 103: 1752-1758.
59. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
60. Vardi Y, Dayan L, Apple B, Gruenwald I, Ofer Y, Jacob G. Penile and systemic endothelial function in men with and without erectile dysfunction. Eur Urol 2008. [in press]
61. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-8.
62. Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 2003; 107: 2805-2809.
63. Wu WC, Sharma SC, Choudhary G, Coulter L, Coccio E, Eaton CB. Flow-mediated vasodilation predicts the presence and extent of coronary artery disease assessed by stress thallium imaging. J Nucl Cardiol 2005; 12: 538-544.
64. Shechter M, Issachar A, Marai I, Koren-Morag N, Freinark D, Shahar Y, et al. Long-term association of brachial artery flowmediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. Int J Cardiol 2008. [in press]
65. Corrado E, Rizzo M, Coppola G, Muratori I, Carella M, Novo S. Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: A 24month follow-up study. Coron Artery Dis 2008; 19: 139-44.
66. Ucar G, Secil M, Demir O, Demir T, Comlekci A, Uysal S, et al. The combined use of brachial artery flow-mediated dilatation and carotid artery intima-media thickness measurements may be a method to determine vasculogenic erectile dysfunction. Int J Impot Res 2007; 19: 577-583.
67. Kovács I, Császár A, Toth J, Siller G, Farkas A, Tarján J, et al. Correlation between flow-mediated dilation and erectile dysfunction. J Cardiovasc Pharmacol 2008; 51: 148-53.
68. Stuckey B, Walsh J, Ching H, Stuckey A, Palmer N, Thompson P, et al. Erectile dysfunction predicts generalised cardiovascular disease: Evidence from a case-control study. Atherosclerosis 2006; 194: 458-64
69. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-605.
70. Agabiti-Rosei E, Mancia G, O'Rourke MF, Roman MJ, Safar ME, Smulyan H, et al. Central blood pressure measurements and antihypertensive therapy: A consensus document. Hypertension 2007; 50: 154-60.
71. Nigam A, Mitchell GF, Lambert J, Tardif JC. Relation between conduit vessel stiffness (assessed by tonometry) and endothelial function (assessed by flow-mediated dilatation) in patients with and without coronary heart disease. Am J Cardiol 2003; 92: 395-9.
72. Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large artery stiffness: From physiology to pharmacology. Hypertension 2004; 44: 112-6. 58.
73. Kaya C, Ergelen M, Ilktac A, Karaman MI. Impaired elasticity of aorta in patients with erectile dysfunction. Urology 2007; 70: 558-62.
74. Boger RH, Vallance P, and Cooke JP. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atherosclerosis 2003; Suppl 4: 1-3.
75. Wierzbicki A, Solomon H, Lumb P, Lyttle K, Lambert-Hammill M, Jackson G. Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Atherosclerosis 2006 Apr; 185: 421-5.
76. Maas R, Wenske S, Zabel M, Ventura R, Schwedhelm E, Steenpass A, et al. Elevation of asymmetrical dimethylarginine (ADMA) and coronary artery disease in men with erectile dysfunction. Eur Urol 2005; 48: 1004-1011.
77. Elesber AA, Solomon H, Lennon RJ, Mathew V, Prasad A, Pumper G, et al. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 2006; 27: 824-831.
78. Cooke JP. ADMA: Its role in vascular disease. Vasc Med 2005; 10: S11-S17.
79. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the AtheroGene Study. CircERes 2005; 97: e53-e59.
80. Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007; 76: 8-18
81. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398-404.
82. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109: 2058-67.
83. Silvestro A, Brevetti G, Schiano V, Scopacasa F, Chiariello M. Adhesion molecules and cardiovascular risk in peripheral arterial disease. Soluble vascular cell adhesion molecule-1 improves risk stratification. Thromb Haemost 2005; 93: 559-563.
84. Witte DR, Broekmans WM, Kardinaal AF, Klopping-Ketelaars IA, van Poppel G, Bots ML, et al. Soluble intercellular adhesion molecule 1 and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other. Atherosclerosis 2003; 170: 147-153.
85. Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, et al. Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res 2007; 30: 541-548.
86. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med 2000; 343: 1179-1182.
87. Eaton CB, Liu YL, Mittleman MA, Miner M, Glasser DB, Rimm EB. A retrospective study of the relationship between biomarkers of atherosclerosis and erectile dysfunction in 988 men. Int J Impot Res 2007; 19: 218-25.
88. Sullivan ME, Miller MA, Bell CR, Jagroop IA, Thompson CS, Khan MA, et al. Fibrinogen, lipoprotein (a) and lipids in patients with erectile dysfunction. Int Angiol 2001; 20: 195-9.
89. Billups KL, Kaiser DR, Kelly AS, Wetterling RA, Tsai MY, Hanson N, et al. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 2003; 15: 231-6.
90. Giugliano F, Esposito K, Di Palo C, Ciotola M, Giugliano G, Marfella R, et al. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrin Invest 2004; 27: 665-9.
91. Esposito K, Giugliano F, Martedi E, Feola G, Marfella R, D'Armiento M, et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2005; 28: 1201-3.
92. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, Rokkas K, Vasiliadou C, Alexopoulos N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J 2006; 27: 2640-8.
93. Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C. Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. Eur Urol 2007; 52: 1590-1600.
94. Naya M, Tsukamoto T, Inubushi M, Morita K, Katoh C, Furumoto T, et al. Elevated plasma plasminogen activator inhibitor type-1 is an independent predictor of coronary microvascular dysfunction in hypertension. Circ J 2007; 71: 348-353.
95. Páramo JA, Beloqui O, Colina I, Diez J, Orbe J. Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects. J Thromb Haemost 2005; 3: 662-4.
96. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 2004; 9: 1118-1135
97. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233-246.
98. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-1241.
99. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction. A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75
100. Lerman A, Cannan CR, Higano SH, Nishimura RA, Holmes DR Jr. Coronary vascular remodeling in association with endothelial dysfunction. Am J Cardiol 1998; 81: 1105-1109.
101. Yetik-Anacak G, Catravas JD. Nitric oxide and the endothelium: History and impact on cardiovascular disease. Vascul Pharmacol 2006; 45: 268-76.
102. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24: 1468-1474.
103. Nurkalem Z, Kaya C, Orhan AL, Zencirci E, Alper AT, Kucuk E, et al. Erectile dysfunction and coronary slow flow: Distinct presentations of endothelial disease. Int J Impot Res 2007; 19: 610-614.
104. Han SH, Bae JH, Holmes DR Jr, Lennon RJ, Eeckhout E, Barsness GW, et al. Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis. Eur Heart J 2008; 29: 1359-69.
105. Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rocchietti-March M, et al. Androgens and penile erection: Evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol 2000; 53: 517-22.
106. Rosano GM, Sheiban I, Massaro R, Pagnotta P, Marazzi G, Vitale C, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 2007; 19: 176-82.
107. Yassin AA, Saad F. Testosterone and Erectile Dysfunction. J Androl 2008; 29: 593-604.
108. Ma RC, So WY, Yang X, Yu LW, Kong AP, Ko GT, et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes, J Am Coll Cardiol 2008; 51: 2045-50.
109. Cooke JP and Dzau VJ. Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
110. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-1672.
111. Lerman A, Zeiher A. Endothelial Function: Cardiac Events. Circulation 2005; 111; 363-368.
112. Hansson G. Inflammation, atherosclerosis and coronary artery disease. N Engl Med 2005; 352: 1685-95.
113. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88; 756-762.
114. Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 2005; 25: 2043-2053.
115. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96: 85M-93M.
116. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, et al. Effect of lifestyle changes on erectile dysfunction in obese men: A randomized controlled trial. JAMA 2004; 291: 2978-2984.
117. Esposito K, Ciotola M, Giugliano F, De Sio M, Giugliano G, D'armiento M, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 2006; 18: 405-410.
118. Bank AJ, Kelly AS, Kaiser DR, Crawford WW, Waxman B, Schow DA, et al. The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. Vasc Med 2006; 11: 251-7.
119. Castro MM, Rizzi E, Rascado RR, Nagassaki S, Bendhack LM, Tanus-Santos JE. Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur J Pharmacol 2004; 498: 189-94.
120. Herrmann HC, Levine LA, Macaluso J Jr, Walsh M, Bradbury D, Schwartz S, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med 2006; 3: 303-308.
121. Miner M, Billups KL. Erectile dysfunction and dyslipidemia: Relevance and role of phosphodiesterase type-5 inhibitors and statins. J Sex Med 2008; 5: 1066-78.
122. Solomon H, Samarasinghe YP, Feher MD, Man J, Rivas-Toro H, Lumb PJ, et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 2006; 60: 141-145.
123. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-2363.
124. Gelosa P, Cimino M, Pignieri A, Tremoli E, Guerrini U, Sironi L. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag 2007; 3: 567-577.
125. Doumas M, Douma S. The effect of antihypertensive drugs on erectile function: A proposed management algorithm. J Clin Hypertens 2006; 8: 359-64.
126. Speel TG, Kiemeney LA, Thien T, Smits P, Meuleman EJ. Longterm effect of inhibition of the angiotensin-converting enzyme (ACE) on cavernosal perfusion in men with atherosclerotic erectile dysfunction: A pilot study. J Sex Med 2005; 2: 207-212.
127. Düsing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003; 2: 29-34.
128. Baumhäkel M, Schlimmer N, Böhm M. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res 2008; 20: 493-500.
129. Bohm M, Baumhakel M, Probstfield JL, Schmieder R, Yusuf S, Zhao F, et al. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACEIN-tolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J 2007; 154: 94-101.
130. Toblli JE, Cao G, Lombraña A, Rivero M. Functional and morphological improvement in erectile tissue of hypertensive rats by longterm combined therapy with phosphodiesterase type 5 inhibitor and losartan. J Sex Med 2007; 4: 1291-303.
131. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005; 18: 720-30.
132. Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. Circ Res 2007; 101: 441-54.
133. Silvestri A, Galetta P, Cerquetani E, Marazzi G, Patrizi R, Fini, et al. Report of erectile dysfunction after therapy with betablockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003; 24: 1928-32.
134. Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): Benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007; 34: 327-31.
135. Doumas M, Tsakiris A, Douma S, Grigorakis A, Papadopoulos A, Hounta A, et al. Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J Androl 2006; 8: 177-82.
136. Baumhäkel M, Schlimmer N, Büyükafsar K, Arikan O, Böhm M. Nebivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein e-knockout mice. J Pharmacol Exp Ther 2008; 325: 818-23.
137. Francis SH, Morris GZ, Corbin JD. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. Int J Impot Res 2008; 20: 333-42.
138. Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors: the day after. Eur Urol 2007; 51: 75-89.
139. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Phosphodiesterase type 5 inhibitors: Non-erectile dysfunction cardiovascular effects. In Carson C, Goldstein I and Kirby R, ed. Textbook of Erectile Dysfunction, 2nd Edition Informa, Healthcare 2008. [in press]
140. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of phosphodiesterase type-5 inhibitors. [J Sex Med in press]
141. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002; 25: 1336-1339.
142. Vlachopoulos C, Tsekoura D, Alexopoulos N, Panagiotakos D, Aznaouridis K, Stefanadis C. Type 5 Phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. Am J Hypertens 2004; 17: 1040-1044.
143. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40: 1232-1242.
144. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances low-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845-51.
145. Mazo E, Gamidov S, Iremashvili V. The effect of vardenafil on endothelial function of brachial and cavernous arteries. Int J Impot Res 2006; 18: 464-9.
146. Behr-Roussel D, Oudot A, Caisey S, Coz OL, Gorny D, Bernabé J, et al. Daily Treatment with Sildenafil Reverses Endothelial Dysfunction and Oxidative Stress in an Animal Model of Insulin Resistance. Eur Urol 2008; 53: 1272-81.
147. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50: 2136-44.
148. Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med 2008; 25: 37-44.
149. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47: 214-22.
150. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: A pilot study. Int J Impot Res 2007; 19: 200-7.
151. Bocchio M, Pelliccione F, Passaquale G, Mihalca R, Necozione S, Desideri G, et al. Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. Atherosclerosis 2008; 196: 313-9.
152. Morano S, Mandosi E, Fallarino M, Gatti A, Tiberti C, Sensi M, et al. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: A double-blind, placebo-controlled study. Eur Urol 2007; 52: 1768-76.
153. Foresta C, Ferlin A, De Toni L, Lana A, Vinanzi C, Galan A, et al. Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 2006; 18: 484-8.
154. Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Vinanzi C, et al. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: Effect of vardenafil administration and PDE5 expression in the bone marrow. Eur Urol 2007; 51: 1411-7.
155. Kugiyama K, Yasue H, Okumura K, Ogawa H, Fujimoto K, Nakao K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 1996; 94: 266-71.
156. Fung E, Fiscus RR, Yim AP, Angelini GD, Arifi AA. The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest 2005; 128: 3065-73.
157. Vlachopoulos C, Hirata K, O'Rourke MF. Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med 2003; 8: 243-8.